跳至主要内容
临床试验/ACTRN12610000181000
ACTRN12610000181000招募中3 期

In patients with paroxysmal lone atrial fibrillation can oral magnesium compared to placebo reduce the incidence of atrial fibrillation?

euroscience Department, Barwon Health0 个研究点目标入组 200 人开始时间: 2010年3月1日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients with paroxysmal lone atrial fibrillation documented by an electrical tracing (minimum of 2 episodes within prior 12 months)

排除标准

  • 1.Renal Failure with a serum urea > 10 mmol/L.
  • 2.Untreated hyperthyroidism.
  • 3.Atrial fibrillation with associated cardiac disease with an abnormal transthoracic echocardiogram; e.g. cardiomyopathy, enlarged left atrium, valvular heart disease.
  • 4.Symptomatic Inflammatory Bowel disease.
  • 5.Currently taking Magnesium supplementation.
  • 6.Daily consumption of alcohol >4 standard drinks.
  • 7.Transient paroxysmal atrial fibrillation secondary to other reversible disorders (e.g., thyrotoxicosis, cardiac or thoracic surgery, pneumonia, severe anemia)

研究者

发起方
euroscience Department, Barwon Health

相似试验